Peripheral mechanisms involved in the pressor and bradycardic effects of centrally administered arachidonic acid


AYDIN C. , YALÇIN M.

PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, vol.78, no.6, pp.361-368, 2008 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 78 Issue: 6
  • Publication Date: 2008
  • Doi Number: 10.1016/j.plefa.2008.04.007
  • Title of Journal : PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
  • Page Numbers: pp.361-368

Abstract

In the current study, we aimed to determine the cardiovascular effects of arachidonic acid and peripheral mechanisms mediated these effects in normotensive conscious rats. Studies were performed in male Sprague Dawley rats. Arachidonic acid was injected intracerebroventricularly (i.c.v.) at the doses of 75, 150 or 300 mu g and it caused dose- and time-dependent increase in mean arterial pressure and decrease in heart rate in normal conditions. Maximal effects were observed 10 min after 150 and 300 mu g dose of arachidonic acid and lasted within 30 min. In order to evaluate the role of main peripheral hormonal mechanisms in those cardiovascular effects, plasma adrenaline, noradrenaline, vasopressin levels and renin activity were measured after arachidonic acid (150 mu g; i.c.v.) injection. Centrally injected arachidonic acid increased plasma levels of all these hormones and renin activity. Intravenous pretreatments with prazosin (0.5 mg/kg), an alpha(1) adrenoceptor antagonist, [beta-mercapto-beta,beta-cyclopentamethylenepropionyl(1), O-Me-Tyr(2)-Arg(8)]-vasopressin (10 mu g/kg), a vasopressin V-1 receptor antagonist, or saralasin (250 mu g/kg), an angiotensin II receptor antagonist, partially blocked the pressor response to arachidonic acid (150 mu g; i.c.v.) while combined administration of these three antagonists completely abolished the effect. Moreover, both individual and combined antagonist pretreatments fully blocked the bradycardic effect of arachidonic acid.